Rob Sprawson
Partner & CFO at Cambridge Innovation Capital
Rob Sprawson
Partner & CFO at Cambridge Innovation Capital
Greater Cambridge Area
Overview
Work Experience
Partner & CFO
2015 - Current
Cambridge Innovation Capital backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. Since our inception in 2013, we have raised over £500 million to invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics.
Director and Owner
2010 - 2015
Owner/director of a consulting company providing strategic, financial and transaction based advice and support to boards and senior management teams of both private and listed businesses.
Finance Director
2010 - 2015
Lumora, a spin-out from the University of Cambridge, applies its proprietary, and commercially validated, molecular diagnostic technologies in sample preparation, amplification and detection to produce novel workflow based solutions to reduce the complexity of molecular testing.
Chief Financial Officer
2011 - 2015
Altacor is an ophthalmic specialty pharmaceutical company with a portfolio of prescription and OTC products, primarily for dry eye through its Clinitas® range. Altacor was a venture capital backed business until its disposal in 2014.
Chief Financial and Commercial Officer
2010 - 2011
Warwick Ventures Limited, the technology commercialisation office of the University of Warwick, is responsible for ensuring that intellectual property arising from the University's annual research spend of c.£120 million is appropriately protected and commercialised.
Chief Financial Officer
2005 - 2009
MMI was an AIM listed life sciences company that identified, acquired and developed world-class compounds and technologies for the treatment of cancer. MMI managed the preclinical and early clinical development of drug candidates whilst pursuing collaborative opportunities with pharmaceutical partners.
Senior Manager, Corporate Finance
1992 - 2005
Provided advice on a full range of mergers and acquisitions and financial advisory services (including acquisitions, disposals, MBOs, spin-outs and raising finance) to companies in the pharmaceutical and biotechnology sectors.
Education
BA
1989 - 1992